IL-35 is expressed in tumor-infiltrating lymphocytes of breast cancer. The expression level of IL-35 in TILs may be a valuable prognostic factor for IDC. High plasma IL-35 levels were associated with late TNM stage in IDC. Increased IL-35+ populations in the TILs may impair antitumor immune response.